Filing Flows › Haemonetics (HAE) › Q1 FY27
Haemonetics (HAE) Q1 FY27 earnings results (first quarter fiscal 2027)
10-Q filed Aug 6, 2026
Haemonetics (HAE) reported revenue of $339M for the first quarter fiscal 2027 (Q1 FY27), +6% from a year earlier and -2% from the quarter before. Operating margin was 16.9%, net earnings $33.0M (9.7% of revenue).
Haemonetics, Q1 FY27: revenue $339M (+6% year over year), operating margin 16.9%, net earnings $33.0M, operating cash flow $52.3M. The chart follows the revenue to costs, profit and cash.
| Q1 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $339M | -2% | +6% |
| Gross profit | $203M | +2% | +5% |
| Operating profit | $57.5M | — | +7% |
| Net earnings | $33.0M | — | -3% |
| Operating cash flow | $52.3M | -26% | +201% |
| Free cash flow | $39.1M | — | — |
What changed
Revenue was $339.4M in Q1 FY27, up 6% year over year and down 2% from the previous quarter. Apheresis was the largest line at 56% of revenue. Apheresis added $9.6M year over year (up 5%), 53% of the total change.
Gross margin was 59.8%, down 0.1 points from Q1 FY26. Operating profit was $57.5M, a 16.9% margin (up 0.2 points year over year). Of the extra revenue versus Q1 FY26, 20% reached operating profit, above the 17% margin then. Operating expenses grew 5% against revenue growth of 6%. Net earnings were $33.0M, down 3% year over year. The effective tax rate was 30.6%.
Operating cash flow was $52.3M (up 201% year over year), 159% of net earnings. Non-cash charges added back $27.1M of depreciation and amortization and $9.3M of share-based compensation. Working capital and other items used $17.1M. After capital expenditures, net ($7.7M) and itions to Haemonetics equipment ($5.6M), free cash flow as the company reports it was $39.1M.
Questions
What was Haemonetics' revenue in the first quarter fiscal 2027?
Haemonetics (HAE) reported revenue of $339M for the first quarter fiscal 2027 (Q1 FY27), +6% from a year earlier and -2% from the quarter before.
Was Haemonetics profitable in the first quarter fiscal 2027?
Operating profit was $57.5M (16.9% of revenue) and net earnings $33.0M.
Source: Haemonetics 10-Q on SEC EDGAR.